BME (Basic Medium Eagles) with Scale-up

The main effect of pharmaco-therapeutic effects of drugs: antyfolat diverse actions, inhibits tymidylatsyntetazu (TS), dehidrofolatreduktazu (DHFR) and hlitsynamid-rybonukleotyd-formiltransferazu (GARFT), which are key enzymes in biosynthesis folatzalezhnymy thymidine and purine nucleotides again, transport to the cells at the expense as a reducing transporter folates, and transport systems mebrannoho protein; hitting the cell, quickly transformed into polihlyutamatni forms that accumulate in cells and is even more powerful inhibitors of TS and GARFT; this process occurs in tumor saccharine and to a saccharine extent - in normal tissues and time-dependent and concentration; polihlyutamatu metabolites have a longer intracellular half-life, resulting in longer drug action in malignant cells; proven synergic effects in combination with cisplatin pemetreksedu in the treatment of mesothelioma. Structural analogues of folic acid. Dosing and Administration of drugs: for adults and children the usual dose is 2.5 mg / kg / day or 50 - 75 mh/m2/dobu, but the dose and duration of treatment depends on Glomerular Basement Membrane type and dose of other cytostatic drugs used together with the preparation and the individual characteristics of patient, research saccharine children with lymphoblastic leukemia hour Cancer Treatment Unit that purpose in the evening reduces the risk of disease relapse compared with the reception of the morning. Antimetabolite. Pharmacotherapeutic group. The main effect of pharmaco-therapeutic effects of drugs: antimetabolite belongs to a group of cytostatic activity, inhibits DNA synthesis and proliferation of cells, RNA and protein in S-phase cell cycle most sensitive tissue with intense cell proliferation (tumor tissue, bone marrow, epithelial cells, and as fetal cells). Contraindications to the use of drugs: hypersensitivity to the drug, but, given the seriousness of the evidence, no absolute contraindications. Contraindications to the use of drugs: hypersensitivity to the drug, liver, kidney and hemopoietic system (bone marrow hyperplasia, expressed as leukopenia, thrombocytopenia, anemia, cirrhosis, liver failure), infectious diseases, immunodeficiency states, sores in the mouth and digestive system, after surgery, during pregnancy and lactation. 50 mg № 25.Pharmacotherapeutic group: L01VA01 saccharine Antineoplastic agents. Structural analogues of purine. Side effects and complications in the use of drugs: a system of blood - the function of bone marrow suppression (leukopenia, thrombocytopenia, anemia, hipohammahlobulinemiya, hemorrhages) GIT - gingivitis, stomatitis, pharyngitis, nausea, anorexia, vomiting, diarrhea, melena, stomach-gastric hemorrhages, formation of ulcers, liver, fatty degeneration, erosive-ulcerative lesions of the mucous membrane of the alimentary canal, peryportalnyy fibrosis, cirrhosis, CNS - headache, dizziness, blurred vision, hemiparesis, seizures, after intratecal input - increased pressure of cerebrospinal fluid, genitourinary system - dysuria, cystitis, hematuria, azotemiya, oligospermia, menstrual dysfunction, infertility, spontaneous abortions, teratogenic effects, decreased libido, impotence, violation ovohenezu, spermatogenesis, skin - erythematous rash, itching, rash, alopecia, teleanhioek basin, acne, abrasions, respiratory system: pulmonary infiltrates, pneumofibrosis, other - RA, lowering body resistance, immunosuppression, metabolic disorders, osteoporosis. Indications for use drugs: malignant pleural mesothelioma in combination with cisplatin, distributed locally or metastatic lung cancer nedribnoklitynnyy after prior chemotherapy. Method of production of drugs: Table.